

Multifunctional antimicrobial peptides: therapeutic targets in several human diseases


Mohamed Zaiou

Received: 6 August 2006 / Revised: 10 October 2006 / Accepted: 10 November 2006 / Published online: 10 January 2007
© Springer-Verlag 2007

Abstract Antimicrobial peptides have emerged as promising agents against antibiotic-resistant pathogens. They represent essential components of the innate immunity and permit humans to resist infection by microbes. These gene-encoded peptides are found mainly in phagocytes and epithelial cells, showing a direct activity against a wide range of microorganisms. Their role has now broadened from that of simply endogenous antibiotics to multifunctional mediators, and their antimicrobial activity is probably not the only primary function. Although antimicrobial peptide deficiency, dysregulation, or overproduction is not known to be a direct cause of any single human disease, numerous studies have now provided compelling evidence for their involvement in the complex network of immune responses and inflammatory diseases, thereby influencing diverse processes including cytokine release, chemotaxis, angiogenesis, wound repair, and adaptive immune induction. The purpose of this review is to highlight recent literature, showing that antimicrobial peptides are associated with several human conditions including infectious and inflammatory diseases, and to discuss current clinical development of peptide-based therapeutics for future use.

Keywords Antimicrobial peptides · Inflammatory diseases · Innate immune system · Infection · Host defense

M. Zaiou (✉)
INSERM 525 E4, Faculté de Pharmacie,
Université Henri Poincaré Nancy I,
30 Rue Lionnois,
54000 Nancy, France
e-mail: Mohamed.Zaiou@pharma.uhp-nancy.fr



Introduction

Antimicrobial peptides (AMPs), also known as genetically encoded antibiotic peptides, are conserved components of the innate immune response [1, 2]. They are produced in many organisms including bacteria, insects, plants, and vertebrates, where they represent a defense system [3–5]. In mammals, these peptides function mainly in phagocytic cells of the immune system to kill engulfed or invasive bacteria and in mucosal epithelial cells to prevent colonization of host tissues by pathogens [1, 6]. In the past two decades, numerous antimicrobial peptide families from many living organisms have been described. In humans, three distinct groups were characterized, including defensins, cathelicidins, and histatins. Additional peptides that have been identified include RNase 7, granulysin, hepcidin, dermacidin, and lactoferrin. As of 2006, the inventory of AMPs comprises about 900 peptides of different origins, and these peptides have been listed in a database in Trieste (<http://www.bbcm.univ.trieste.it/~tossi/pag1.htm>). Additional information with

regard to these peptides is also available from another website: <http://aps.unmc.edu/AP/main.htm>. Medline database search using the PubMed interface with “antimicrobial peptides” as key word also shows more than 7,000 references with new references added every week.

AMPs have potent activities against a broad range of microorganisms that covers gram-positive and -negative bacteria, fungi, parasites, and enveloped viruses [7, 8]. Several excellent review articles have examined the role of these peptides in the protection of a variety of human tissues [9–11]. The precise details of their mechanism of action remain unknown. However, it is generally accepted that the positively charged peptides act directly on the negatively charged cellular membranes of bacterial cells, causing an increase in membrane permeability, which then leads to rapid cell death [12, 13]. Other mechanisms of action, including activity on intracellular targets after membrane permeabilization, have been proposed. Examples of intracellular activity include the activation of autolytic enzymes and the inhibition of DNA and protein synthesis [13, 14]. Buforin II has been shown to enter the cell and accumulates in the bacterial cytoplasm where it inhibits cellular functions by binding to DNA and RNA [15]. Attacins block the synthesis of integral membrane proteins [16]. PR-39 was reported to inhibit DNA synthesis [17]. Interestingly, pyrrolicin, an insect peptide, was demonstrated to kill bacteria by binding to a protein target called DnaK [18], thereby preventing it from performing its protein-repair function, leading to death of the bacteria. Recently, a different mechanism has been proposed for the θ -defensin, retrocyclin 2, which blocks influenza virus infection by cross-linking and immobilizing surface glycoproteins, resulting in the inhibition of viral entry into the cell [19]. Together, these data make AMPs a very attractive target for clinical development to treat conditions where traditional antibiotics are becoming less effective. As AMP research has proliferated, the repertoire of biological roles of AMPs has expanded to a number of other functions (Fig. 1). These include (1) endotoxin neutralization, a property that allows detoxification of LPS [20], (2) chemokine-like activity, based on chemokine structural motif similarity that allows AMPs such as β -defensins to interact with certain chemokine receptors [21], and (3) immunomodulatory activities linking innate to adaptive immune responses [22, 23].

More recently, there has been growing interest in the role of these peptides in several inflammatory conditions including psoriasis, arthritis, respiratory diseases, atherosclerosis, and wound repair. These novel findings will be summarized in this review. It is hoped that a better understanding of how AMPs contribute to these diseases will provide important clues to the “patho-etologies” of many of these complex conditions that have often been

labeled as idiopathic when no cause is known. These researches would pave the way for the development of novel therapeutic drugs.

Antimicrobial peptides against infectious diseases

Why AMPs? Although the discovery and the development of antibiotics during the mid-twentieth century provided potent antimicrobial drugs with high specificity, increasing antibiotic resistance in microorganisms and new emerging pathogens have become a major problem in our society [24]. Several human pathogens are now becoming resistant to a number of clinically significant antibiotics, causing a crisis in the treatment and management of infectious diseases. Strains of *Mycobacterium tuberculosis*, *Enterococcus faecium*, and *Pseudomonas aeruginosa* are no longer easily treated with antibiotics, and increased resistance is observed in other important human pathogens such as *Staphylococcus aureus* and *Streptococcus pneumoniae*. The resistance phenomenon has been attributed to the overuse of antibiotics and the increasing number of immunocompromised patients who have alterations in phagocytic, cellular, or humoral immunity. The diminished effectiveness of current therapies and the widespread resistance has prompted interest in the search for new antibiotics as alternative treatments. A developing area of study using natural peptides with antimicrobial activity may offer the solution for the encountered resistance and hold promise for development of new therapeutic agents.

Evidences for antimicrobial activity of natural peptides

A growing body of evidence has demonstrated that AMPs work as antibiotics. Data from in vitro as well as from in vivo models have provided compelling evidence that these peptides protect against a range of microorganisms including bacteria, enveloped viruses, fungi, and even certain parasites.

AMPs against bacteria Direct antibacterial activity of AMPs has been demonstrated by a number of studies. Depleted levels of antibiotic peptides have been shown to be associated with several pathologic conditions. For instance, in humans, patients with a specific granule deficiency syndrome lack α -defensins and suffer from severe and frequent bacterial infections [25]. Others with a condition known as morbus Kostmann suffer from frequent oral bacterial infections and severe periodontal disease, which correlates with a deficiency in the human cathelicidin peptide LL-37 and human neutrophil peptides (HNP1-3) [26]. Low expression of LL-37, human β -defensin (hBD)-2, and hBD-3 in skin lesions caused by atopic dermatitis coincides with enhanced susceptibility to




Fig. 1 Multifunctions of antimicrobial peptides in infectious and inflammatory diseases. After their release from various cell types after activation by microbes or inflammatory mediators, AMPs show a number of functions, including antimicrobial activity and

modulation of the inflammatory response in different inflammatory diseases. Primary potential mechanisms of action of these peptides are *highlighted*

skin infections [27]. In rodent models, cathelicidins can control bacterial load and prevent mortality when administered after bacterial challenge [28, 29]. β -defensin-1 and CRAMP (*cnlp*) gene in knockout mice are more susceptible to and fail to clear infections [30, 31]. Conversely, overexpression of human defensins protected mice against enteric salmonellosis [32]. Systemic administration of nisin, a lanthionine-containing peptide from *Lactococcus lactis*, protected mice against *S. pneumoniae* infection [33]. The antibiotic nature of AMPs was also confirmed by a recent study demonstrating that in transgenic mice, overexpression of the porcine cathelicidin PR-39 enhanced resistance and protection of these animals against group A *Streptococcus* [34]. Lately, a fungal peptide named plectasin, belonging to the family of defensins, has shown antibacterial activity particularly against *S. pneumoniae*, including strains resistant to conventional antibiotics [35].

Although genetically modified mice contribute significantly to the studies of AMPs in vivo, evaluation of how specific peptides contribute to the host response after pathogenic challenge is complicated by a number of issues

including (a) presence of large peptide families including 22 alpha-defensins in mice or 35 beta-defensins in humans may lead to functional redundancy, (b) other proteins such as lysozyme and lactoferrin also contribute to host defense, and (c) many AMPs have overlapping antimicrobial activity against gram-positive and gram-negative bacteria. Therefore, to identify the unique contribution of each AMP to disease, specific AMPs in knockout mice and relevant disease models will need to be studied.

Another method used to demonstrate the antibiotic properties of these peptides consisted of gene therapy approach in which mice were inoculated with an adenovirus vector containing the DNA for the human peptide LL-37 [36]. Success of this approach was corroborated by demonstration that overexpression of porcine PR-39 or human LL-37 in keratinocytes transduced with a recombinant lentivirus enhanced bacterial killing [34, 37]. AMP cutaneous gene therapy has also been successfully used in infected wounds and burns [38, 39]. However, although the concept of developing AMPs as antibiotics appears promising, concerns about bacterial resistance to these peptides

have been raised. Experimental analysis has identified a number of mechanisms of bacterial resistance to AMPs including altered cell surface charge, active efflux, production of proteases or trapping proteins, and modification of host cellular processes (reviewed in [40, 41]). Therefore, knowledge of the molecular basis of bacterial resistance to AMPs may provide clues on how to circumvent potential resistance problems. This research will build a basis for the development of AMPs as an alternative therapy to conventional antibiotic agents for the treatment of drug-resistant pathogens.

AMPs against viruses Apart from the antibacterial activity, AMPs such as defensins also possess antiviral activity. Based on the pattern of cysteine connectivity, mammalian defensins are classified into alpha and beta families. Recently, a circular form of AMPs called θ -defensin has been characterized in macaques, whereas in humans, the gene coding this peptide had been silenced by mutation [42]. Different studies have reported that defensins inhibit viral replication [43, 44]. For example, the α -defensins target the human immunodeficiency virus (HIV) activity by directly inactivating viral particles and affecting the ability of the virus to replicate within CD4 cells [45]. Human α -defensins HNP-1 to -3 and HD-5 have been shown to block papillomavirus infection [46]. Retrocyclin 2, a synthetic θ -defensin peptide that humans do not synthesize due to a mutation in the corresponding human gene, has the capacity to block influenza virus infection [19]. Human β -defensins can also block HIV-1 replication, and interestingly, a single-nucleotide polymorphism in a β -defensin gene has been associated with clinical manifestation of HIV-1 infection, suggesting that the human β -defensins play an important role in host defense against HIV [47]. Cathelicidins, in contrast, have an inhibitory effect on lentiviral replication in vitro [48], and LL-37 appears capable of interfering with vaccinia virus replication in vitro and in mice [49]. Dermaseptin S4, a 28-residue AMP isolated from frog skin, attenuates HIV infection in vitro [50]. Other AMPs from frog skin including caerin 1.1, caerin 1.9, and maculatin 1.1 have also demonstrated inhibition of HIV in vitro [48].

How AMPs inhibit viral entry into cells? HIV entry into a target cell is facilitated by its gp120/gp41 glycoprotein (env) interaction with CD14 [51] and a coreceptor, usually CCR5 or CXCR4 [52]. Generally, defensins inhibit HIV entry into the cell by inhibiting one of these mechanisms. For instance, θ -defensin has been shown to prevent HIV-1 env-mediated fusion by binding gp41 and blocking its 6-helix bundle formation [53]. hBD-3 has been reported to inhibit HIV infection by competing with stromal-derived factor, the natural ligand for CXCR4 [54]. Therefore, AMPs, in

particular defensins, have clear anti-HIV-1 activity, and their broader anti-viral functions await further exploration.

AMPs against fungi The increasing incidence and severity of invasive mycoses and the resistance of fungal pathogens to currently available antifungal drugs have led scientists to explore the antifungal properties of AMPs. To date, approximately 100 peptides have been investigated for their capacity to counteract fungal infections, particularly those caused by *Candida spp.* [55]. *Candida spp.* have emerged as the fourth most common cause of bloodstream infections in the USA. Human HNP-1 and HNP-2 have shown fungicidal activity against *Candida albicans* and inhibited significantly the growth of *Cryptococcus neoformans* [56]. Rabbit NP-1, NP-2, and NP-3 also demonstrated good efficacy against *C. albicans* [57]. Histatins are another family of peptides with antifungal activity that are selectively secreted by the human parotid and submandibular glands. Among these peptides, histatins 1, 3 and 5 have been identified and characterized earlier, and their differential fungicidal activity against *C. albicans* has been determined [58]. Additional evidence for the role of AMPs in the protection against fungi has come from a study showing that low levels of histatins from saliva in a group of HIV patients correlated with higher incidence of oral candidiasis [59]. Interestingly, not all strains of *Candida* are sensitive to the action of naturally occurring AMPs. A recent study reported that *Candida glabrata* shows resistance to histatins as well as to magainins [60]. The major mechanism(s) of action by which these peptides inhibit fungi is not clear yet. However, several modes of action have been proposed including binding to and disruption of the outer membrane [61], resulting in leakage of important intracellular contents, and interaction with specific internal targets once they penetrate the cell [62]. Together, these studies have provided evidence that cationic peptides and particularly histatins may represent a new generation of compounds for the treatment of oral fungal infections.

AMPs against protozoa Early studies have demonstrated antiprotozoan activity of AMPs [63, 64]. Since then, considerable research efforts have been directed toward understanding the activities of these peptides against parasites transmitted by insect vectors. Recently, the potential activities of defensins and cathelicidins against the African trypanosome *Trypanosoma brucei* have been explored [65]. *T. brucei* is the vector-borne protozoan parasite that causes sleeping sickness, a disease associated with significant morbidity and mortality in both humans and animals. This study clearly demonstrated the effectiveness of peptides against parasites by disruption of their cell membrane integrity. Further investigation has shown that administration of cathelicidin AMPs to mice with late-stage *T. brucei*

infection rapidly improved parasitemia and prolonged survival [65]. These studies provide evidence for the use of AMPs in the treatment of parasitic diseases and invite more research that examines the role of AMPs in the control of parasitic infections.

Antimicrobial peptides and inflammatory diseases

A number of studies have suggested an association between the activation of innate immune mechanisms and the pathogenesis of inflammatory diseases. Recruitment of inflammatory cells and accumulation of chemokines and proinflammatory cytokines are hallmarks of an inflammatory state. Immune cell infiltrates are the primary source of host antimicrobial agents including AMPs, and released AMPs serve to amplify inflammation. In this context, different studies reported that AMPs including LL-37 may be involved in the regulation of inflammation by activating chemokine release from different cell types [66–68].

Apart from a central role in prevention and clearance of infections, AMPs exhibit an array of ever-expanding functions [69, 70]. The importance of AMPs in inflammatory conditions has now been expanded to include the following: psoriasis, respiratory disorder, inflammatory lung disease, inflammatory bowel disease (IBD), rheumatoid arthritis, and atherosclerosis (Table 1). The potential implication of a role of natural peptides in these diseases will be the major focus of our next discussion.

AMPs and skin diseases

Psoriasis is a common immune-mediated chronic skin disease that comes in different forms and differing levels of severity. Study of psoriatic-scale extracts revealed the presence of several AMPs including LL-37, human neutrophil defensin 1-3, RNase 7, and lysozyme (reviewed in [71, 72]). These peptides are believed to protect inflamed skin from microbial infections, as evidenced by the fact that patients who have psoriasis rarely suffer from skin infections, whereas patients with atopic dermatitis have increased skin infection rate with *S. aureus* [27]. In line with this observation, there exists a good correlation between atopic dermatitis and an impaired innate defense of human skin [73]. High-level expression of AMPs is seen in other pathologic conditions. For instance, hBD-2 and HNP are abundant in lesions of superficial folliculitis, a common skin disease characterized by inflammation of the hair follicle and infection with *S. aureus* [74]. Furthermore, human LL-37 has been shown to be induced in systemic lupus erythematosus and contact dermatitis [75]. From these diverse studies, it is becoming clear that AMPs are

involved in skin diseases. However, their role in pathophysiology of inflamed skin tissues is not fully understood. Therefore, future studies must focus on the purported dual functions of AMPs, namely, its antimicrobial activity and its modulation of inflammatory response.

Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit that widely affects adolescents and young adults (reviewed in [76]). The main events in the development of an inflammatory acne vulgaris lesion involve *Propionibacterium acnes* colonization and proliferation, which has shown resistance to conventional antibiotics. Because of their ability to neutralize endotoxins and consequently to inhibit the secretion of proinflammatory cytokines (e.g., TNF- α , IL-1) by host cells, cationic peptides could be potential candidates for treatment of acne. Granulysin is an antimicrobial peptide of the saponin-like family reported to be present in acne lesions. Recently, it has been reported that granulysin-derived peptides kill *P. acnes* effectively [77] and possess anti-inflammatory effects, as demonstrated by the suppression of *P. acnes*-stimulated cytokine release. Study of another peptide designated MX-594AN, which is under clinical development by Migenix, has demonstrated significant decrease in lesion counts of acne vulgaris in humans [78]. Taken together, these studies suggest that AMPs may be useful as agents for the treatment of acne. Hence, development of peptide-based drugs, preferentially applied topically, should be one area of research focus to resolve skin infections such as acne infection and other worse conditions.

AMPs and respiratory and lung disorder

Respiratory secretions have microbicidal properties mediated by their constituent antimicrobial peptides/proteins including lysozyme, lactoferrin, secretory leukocyte protease inhibitor (SLPI), defensins, and cathelicidins. These molecules are produced by airway epithelial and inflammatory cells and are involved in many processes such as host defense, stimulation of adaptive immune response, and modulation of inflammatory response of lung disease [79]. Evidence for their role in lung disorder came from a number of recent studies describing the alteration of antimicrobial concentration in several pulmonary disease states [80]. Increased defensin levels were observed in cystic fibrosis, diffuse panbronchiolitis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and lung transplant [81, 82]. Cystic fibrosis, a genetic disease associated with recurrent bacterial infections of the airways and inflammation, represents one illustration of the implication of AMPs in human pathologies. The defective chloride channel causing the disease increases salinity of the alveolar fluid and thus impairs the bactericidal activity against *P. aeruginosa* of β -defensins, which are salt

Table 1 Expression level and proposed functions of antimicrobial peptides/proteins in various human inflammatory diseases

Disease state	Peptides	Expression levels and potential functions
Skin inflammatory diseases		
Psoriasis	LL-37, defensins	Overexpressed, absence of <i>S. aureus</i> [27]
Atopic dermatitis	LL-37, defensins	Downregulated, presence of <i>S. aureus</i> [27]
Lupus, erythematous, and contact dermatitis	LL-37	Increased [75]
Acne vulgaris	MX-594 AN Granulysin	Inhibits <i>P. acne</i> [78] Kills <i>P. acne</i> , anti-inflammatory action [77]
Respiratory diseases		
Cystic fibrosis	LL-37, β -defensins	Reduced antimicrobial activity due to salt accumulation [7]
Periodontal disease		
	Defensins	Reduced in saliva of patients with oral candidiasis [142]
	LL-37	Absent in patients with congenital neutropenia [26]
	Histatin 5	Protects periodontium from bacterial infection [89] and prevents biofilm formation [90]
Inflammatory bowel disease		
Crohn's disease		
	HD5 and HD6	Deficient expression in Paneth cells
	HD5 and HD6	Reduced in CD patients with Nod2 mutation [91]
	LL-37	Expression is altered [91]
Ulcerative colitis	HD5, 6; hBD2–4	Upregulated in patients with UC [95]
Cancer		
	Magainin II	Toxic effect against cancer cell lines melanoma, breast and lung cancer, lymphoma, and leukemia [97, 98]
	Insect cecropins	Lyse tumour cells [100]
	Bovine lactoferrin	Inhibits lung and liver metastasis of murine melanomas and lymphomas [101] and cytotoxic toward neuroblastoma cells [103]
Atherosclerosis		
	Defensins	Involved in lipoprotein metabolism [111, 113], exhibit antifibrotic activity [111], and regulate angiogenesis [115]
	LL-37	Increased expression in human lesions [118]
Inflammatory articular joints	hBD-3, LL-37	Upregulated in osteoarthritis [124]

sensitive [83]. In this context, overexpression of human LL-37 in lungs of mice inhibited bacterial load and inflammatory response after pulmonary challenge with *P. aeruginosa* [84]. In a further investigation, gene transfer approach restored the expression of LL-37 in a cystic fibrosis xenograft model and restored bacterial killing [85]. Overall, these peptides/proteins act as the first line of defense against pulmonary infection and may amplify the adaptive immune response by inducing the production of cytokines, which promote T cell-dependent cellular immunity and antigen-specific Ig production [86], or by enhancing both cellular (Th1-dependent) and humoral (Th2-dependent) cytokine production and immune responses [87]. Future studies should identify AMPs active against cystic fibrosis-associated pathogens including *P. aeruginosa*, *S. aureus*, and *Burkholderia cepacia*. Additionally, these peptides need to be selected or engineered to retain their activities at a high salt concentration.

AMPs and periodontal disease

Human periodontitis is a multifactorial inflammatory oral disease with a complex pathogenesis. It is initiated by a group of predominantly gram-negative anaerobic bacteria

such as *Porphyromonas gingivalis*, *Bacteroides forsythus*, and *Actinobacillus actinomycetemcomitans*. One primary barrier to infection is the oral mucosa with its innate and adaptive immune processes. Disruption of this tissue can lead to infection by a variety of microbial challenges that can cause periodontal diseases. In line with this observation, patients with a severe congenital neutropenia have AMP deficiency, which is associated with the occurrence of infection and periodontal diseases [26]. A recent study has shown the expression of hBD-1 and hBD-2 peptides in gingival epithelia from periodontally healthy subjects, as well as patients with unsolved chronic periodontitis, suggesting a role of these peptides in periodontal health and disease [88]. Histatin 5, a salivary peptide, was reported to protect the periodontium from host and bacterial enzymes implicated in periodontal disease [89]. More recently, histatin 5 was shown to prevent biofilm formation, thereby reducing denture-induced stomatitis [90]. Thus, salivary AMPs could play a primary role in blocking of periodontal disease initiated by microbes. The knowledge gained from these and future studies will help identify the role of AMPs in periodontal pathogenesis and will provide support for the ongoing attempts to develop these peptides as drugs for the prevention of oral diseases.

AMPs and chronic inflammatory bowel diseases

In the small intestine, Paneth cells are the major source of AMPs that purportedly play a crucial role in intestinal immunity. A breakdown of this functional barrier may lead to aberrant production of defense molecules and consequently to IBD. IBD is a chronic inflammation of the intestinal mucosa often grouped into two major entities: Crohn's disease (CD) and ulcerative colitis (UC).

Crohn's disease is attributed in part to intestinal bacteria that may initiate and perpetuate mucosal inflammation in genetically susceptible individuals [91]. Studies of transgenic and knockout mice support a pivotal role of Paneth cell α -defensins in protection from bacterial pathogens. New data suggest that deficient expression of Paneth cell α -defensins (HD5 and HD6) may contribute to the pathophysiology of CD [91, 92]. These observations are supported by recent findings showing that mice lacking Nod2, an intracellular sensor of bacteria-derived muramyl dipeptide, fail to express cryptidins, equivalents of human α -defensins [93]. Similarly, human α -defensin expression is diminished in CD patients, particularly in those with Nod2 mutations [91]. Besides defensins, cathelicidin peptides also showed alteration of their expression profile in IBD [94].

Ulcerative colitis is considered a consequence of a failing adaptive and/or innate immune system, in particular AMPs, to cope with pathogenic microorganisms in the intestine. It has been demonstrated that the expression of hBD-2 to -4 is upregulated in colonic enterocytes in patients with UC [95] and that HD5, HD6, and lysozyme are overexpressed due to metaplastic Paneth cell differentiation in UC colon [96]. Overall, these data provide compelling evidence supporting the hypothesis that AMPs play an important role in intestinal defense, and reduction in their expression may compromise host defense and initiate inflammatory diseases. The discovery of factors such as Nod2 [93] that have a direct impact on the expression of AMPs may contribute to development of future preventive and treatment strategies against IBD.

AMPs and cancer

Cancer treatment using classical chemotherapy approach presents a number of limitations, including toxicity and development of multi-drug resistance by cancer cells. Several reports have demonstrated that AMPs are emerging as a promising class of new natural drugs with toxic activity towards cancer cells. In this aspect, magainin II was shown to exert cytotoxic effect against a wide range of cancer cell lines including melanoma, breast and lung cancers, as well as lymphomas and leukemias [97, 98]. Further studies carried out in vivo have shown that magainin peptides

improve survival of animals with ascites-producing tumors [97]. More recently, magainin II was reported to exert cytotoxic and antiproliferative efficacy by pore formation in bladder cancer cells but had no effect on normal murine or human fibroblasts [99]. Cecropins, insect-derived cationic peptides, were also found to be effective in lysis of tumor cells including multidrug-resistant tumor cell lines [100]. In contrast, bovine lactoferricin inhibited liver and lung metastasis of both murine melanomas and lymphomas [101] and induced apoptosis in human leukaemia and carcinoma cell lines [102]. In another study, Eliassen et al. [103] reported that lactoferricin B shows cytotoxicity to neuroblastoma cells in vitro and inhibits the growth of neuroblastoma xenograft in nude rats. Interestingly, lactoferricin seems to induce a rapid destabilization of tumor cell cytoplasmic membrane, triggering apoptosis cascades at a dose that does not affect normal fibroblasts or erythrocytes [104]. Moreover, α -defensins were localized to solid epithelial tumors, specifically oral squamous cell carcinoma, lung tumors, and renal cell tumors, suggesting an association of these peptides with cancer development [105–107]. Recently, an association between the overexpression of α -defensin peptides and bladder cancer invasiveness was reported [108]. However, a physiological approach involving animal models will help to better define the biological activity of these peptides toward cancer cells and to clarify the molecular mechanism by which these cells become susceptible to some of the AMPs. So far, at least three mechanisms have been proposed, (1) cell membrane lytic effect, (2) activation of intrinsic pathways of apoptosis via mitochondrial membrane disruption (reviewed in [109]), and (3) certain peptides are potent inhibitors of blood vessel development that is associated with tumor progression; extensive studies need to be performed to prove that these peptides do not destroy vital organs and have lower toxicity toward normal cells. If all these desirable properties are proven, then AMPs could be the next generation of drugs for cancer therapy. Hence, the development of a strategy that can be used to efficiently deliver apoptosis-promoting and/or anti-angiogenic peptides to both tumor cells and tumor vasculature should be another issue to take in consideration.

AMPs and the inflammatory process of atherosclerosis

Atherosclerosis is a complex and chronic inflammatory disease process characterized by the retention and modification of low-density lipoproteins within the wall of blood vessels [110] and the development of local inflammation event. AMPs produced by endothelial cells and neutrophils are present within atheromatous plaques in the cerebral and coronary circulation [111, 112]. The potential role of these peptides in the development of atherosclerosis, including

endothelium dysfunction, has been investigated. In this context, defensins were found to have multiple functions. They participate in the lipoprotein uptake and degradation in the vessel wall [111, 113]. They possess antifibrotic activity [114] and regulate angiogenesis [115, 116]. Lately, animal studies have shown that neutrophil α -defensins cause endothelial cell dysfunction in porcine coronary arteries by reducing endothelium-dependent vasorelaxation [117]. Besides defensins, cathelicidins have also been investigated in the atherosclerosis development process. A sixfold increase in LL-37 transcripts in human atherosclerotic lesions compared with normal arteries was reported [118]. Using gene transfer approach, adenoviral PR-39 was reported to improve blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation [119]. Antimicrobial peptides/proteins have also been associated with an emerging global problem of obesity and diabetes, a complication that leads to increased burden of heart disease. In diabetic patients, an interesting theory on lactoferrin and lysozyme inactivation proposes specific binding of these proteins to glucose-modified proteins bearing advanced glycation end products [120]. These motifs inhibit endogenous bacterial proteins, thereby increasing susceptibility to bacterial infections in the diabetic population. However, a number of questions have not been answered convincingly. For instance, what is the biological significance of these findings? Is increased expression of these peptides beneficial or harmful to the vessel wall? Is there a link between AMP expression and modified lipids known as a major risk factor for the development of atherosclerosis? Because of the high prevalence of atherosclerosis and the resulting complications, clinical studies are needed to explain the significance of the above-mentioned findings.

AMPs and articular joints

For the last couple of years, AMPs have been investigated in articular joint inflammation including pyogenic arthritis, rheumatoid arthritis, and osteoarthritis. Their presence in human articular cartilage has been reported previously [121]. Further studies have revealed an alteration in the expression of these peptides in synovial membrane from patients with inflammatory joint disease [122], suggesting a role in the protection against microbial infection. However, the upregulation of hBD-3 and LL-37 in osteoarthritis without bacterial challenge has led scientists to believe that they have functions other than the ability to kill microbes. This hypothesis was confirmed later by experiments using animal model for osteoarthritis showing an induction of mouse AMPs in the pathogenesis of osteoarthritis in vivo [123, 124]. Of interest is the finding of a report by Varoga and his colleagues [125], showing overexpression of hBD-3 in

osteoarthritis cartilage without bacterial challenge. The observed induction of defensins was attributed to their modulation by proinflammatory cytokines including TNF- α and IL-1, known to regulate AMPs [126, 127]. Together, these findings widen our knowledge of the functional spectrum of AMPs, particularly that of hBD-3, which is a multifunctional peptide with the ability to link host defense mechanisms and inflammation with tissue-remodeling processes in articular cartilage. A full knowledge of the exact function of these intrinsic peptides in articular cartilage and synovial membrane will provide further insight into prevention of human articular joint disease.

AMPs and injury, angiogenesis and wound healing

Angiogenesis is one of the complex biological processes of inflammation and wound repair [128]. For instance, when skin epithelial barrier function is breached as a result of injury, wound repair process requires both recruitment and coordination of numerous cell types including inflammatory cells. Neutrophils and macrophages are among cells that invade wound areas and constitute the major source of several angiogenic growth factors and AMPs such as LL-37, which exerts chemoattractant and angiogenic activity. In fact, the expression of LL-37 was reported to be increased in wounded skin [129]. The biological significance of this alteration is probably the protection of injured tissue until it is restored. Growth factors are of major importance in wound healing. Insulin-like growth factor I and TGF- α have been shown to induce the expression of the antimicrobial protein hCAP-18/LL-37 (human cationic antimicrobial protein of 18 kDa), h β D-3, neutrophil gelatinase-associated lipocalin, and SLPI in human keratinocytes [130]. In this context, mice deficient in SPLI have a deficiency in cutaneous wound repair that is associated with increased inflammation [131]. Another compelling evidence of the role of AMPs in wound repair comes from a study by Heilborn and his colleagues [132] showing that LL-37 peptide is involved in the re-epithelialization of human skin wound, and its reduction is associated with chronic ulcer epithelium. Another potential effect of AMPs is seen in burn wounds. In severely burned patients, there is a relative deficiency in certain AMPs, and these patients have greater risk of infection [133, 134]. A study by Steinstraesser et al. [135] investigated the *in vivo* antimicrobial activity of protegrin-1 using an animal burn model. This study showed a rapid decrease in bacterial counts compared to the controls infected in burn wounds.

Using *in vitro* and *in vivo* models for wound healing, Koczulla et al. [136] have identified another novel biologic activity of human LL-37, which consists of induction of angiogenesis and arteriogenesis. Interestingly, the porcine cathelicidin PR-39, has been shown to induce a robust

angiogenic response in in vivo and in vitro experimental models [137]. In conclusion, the multiple links among AMP expression, increased angiogenesis, and tissue repair involve a number of pathways, including those of toll-like receptors, inflammatory cytokines, and putative “danger” signals. Together, these complicated processes could have several implications, including protection of vulnerable tissue against infection, growth promoting activities, and epithelialization events.

Clinical development of antimicrobial peptides

The challenge at hand is to use current knowledge of AMPs in the design and development of useful drugs. In this respect, biotechnology firms have begun development of new peptide-based compounds that show different and potentially improved resistance profiles compared to early antibiotics. A comprehensive summary of AMP-based therapeutics under development has been published recently [11]. Representative examples of peptides going preclinical or clinical trials are discussed next:

- *Plectasin* (Novozymes) is a defensin peptide that shows good microbicidal activity against antibiotic-resistant bacteria such as those responsible for diseases like pneumonia [35]. Unlike other clinically tested AMPs, plectasin appears to be tolerated at high doses and shows efficacy in treatment of systemic infections. The development of plectasin as a therapeutic agent is currently entering preclinical phase with the anticipation that a product will be approved for clinical use in 8–10 years.
- *P-113* (Dermegen) is a 12-amino acid fragment derived from histatin 5 with anti-candidal activity comparable to that of the parent form. This peptide is in phase I/II clinical trials and is used as mouth rinse for treatment of plaques and gingivitis. Data from a human experimental model showed that P-113 is active against gingivitis and plaques [138].
- *MBI-226* (Migenix) is an Idolicidin analogue in phase III clinical trials. It will be used for the treatment of catheter-related blood stream infection [139].
- *MX-594AN* (Migenix) is an antimicrobial cationic peptide in development that has been formulated as topical treatment for mild to moderate acne vulgaris. MX-594AN is under clinical trials and appears to demonstrate efficacy against all types of acne lesion. Migenix has also developed MX-594AN under the name CLS001, which is tested for topical treatment of rosacea. Phase II trials are due to be completed in 2007.
- *PG-1 protegrin* (Intrabiotics) is a peptide in phase III clinical trial designed for the treatment of peritoneal infections caused by *P. aeruginosa*, *S. aureus*, and methicillin-resistant *S. aureus*.
- *rBPI-21* (Xoma) is a recombinant form of human bactericidal/permeability-increasing (BPI) protein that has reached phase II/III clinical trials and will be used for treatment of meningococcaemia and Crohn’s disease.
- *Helio mycin* (EntoMed) is a peptide derived from insects with antifungal activity, currently in preclinical trials.

In summary, although several clinical trials underlined the broad therapeutic potential of AMP-based drugs, these agents are still at an early stage of technologic maturation, and many hurdles have yet to be overcome.

Future perspectives

Although no peptide has yet reached the drug market, pharmaceutical companies remain enthusiastic about the prospect of developing these novel agents as a new generation of medications. Additionally, researchers are now convinced that these natural peptides have functions beyond those of antimicrobial activities and represent an attractive target for the future design of therapeutic agents. The previous section has provided examples of the promising use of AMPs in the clinical setting. However, there are a few drawbacks to consider. As AMPs are of peptidic nature, they could present the following problems: (1) high manufacturing costs, (2) short half life, (3) lost of activity in physiological conditions [140], (4) application problems, (5) unwanted systemic reactions (aggregation, half-life, or immunoreactivity), and (6) interference with normal flora bacteria that may arise when trying to use those peptides as antibacterial agents [141]. Additionally, there remains a number of unresolved issues to consider: (1) Standardized techniques to assess the activity of these peptides is still unavailable. (2) Molecular regulation mechanisms of certain alpha-defensin genes are poorly defined. Detailed knowledge of how AMPs are regulated will allow researchers to create drugs that directly modulate the expression of specific AMPs to ameliorate the specific disease condition. (3) The ability to target these future medications to the site of disease remains a challenge. AMP gene therapy could be a promising approach to revolutionize treatment of many inflammatory and infectious diseases once strategies such as gene delivery are optimized. In this sense, one of the goals will be to design a system that simultaneously achieves high efficiency, prolonged gene expression, and low toxicity. However, as it was mentioned above, formidable challenges related to AMP properties are still to be faced. (4) Tolerance and toxicity issues of these

peptides need to be addressed, especially as their cationic property make them prone to interact with anionic components of the host cells. An ideal peptide drug would be one that can be tolerated at high dose, resists degradation, and is suitable for topical as well as intravenous administration. 5) Finally, understanding of the role and expression of AMPs both in health and disease remains a challenging area of research.

In conclusion, research that focuses on the above issues should provide further important insights into the pathophysiological roles AMPs play in complex diseases. This knowledge will lay the foundation for the use of these peptides as prototypes of innovative drugs and/or as potential sensors and biomarkers for early detection and prevention of diseases.

References

- Zasloff M (2002) Antimicrobial peptides of multicellular organisms. *Nature* 415:389–395
- Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Microbiol* 3:238–250
- Zaiou M, Gallo RL (2002) Cathelicidins, essential gene-encoded mammalian antibiotics. *J Mol Med* 80:549–561
- Hancock REW, Diamond G (2000) The role of cationic antimicrobial peptides in innate host defences. *Trends Microbiol* 8:402–410
- Bulet P, Stocklin R, Menin L (2004) Anti-microbial peptides: from invertebrates to vertebrates. *Immunol Rev* 198:169–184
- Gantz T (1999) Defensins and host defense. *Science* 286:420–421
- Boman HG (2000) Innate immunity and the normal microflora. *Immunol Rev* 173:5–16
- Gennaro R, Zanetti M (2000) Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. *Biopolymers* 55:31–49
- Bardan A, Nizet V, Gallo RL (2004) Antimicrobial peptides and the skin. *Expert Opin Biol Ther* 4:543–549
- Bevins CL (2006) Paneth cell defensins: key effector molecules of innate immunity. *Biochem Soc Trans* 34:263–266
- Zhang L, Falla TJ (2006) Antimicrobial peptides: therapeutic potential. *Expert Opin Pharmacother* 7:653–663
- Epand RM, Vogel HJ (1999) Diversity of antimicrobial peptides and their mechanisms of action. *Biochim Biophys Acta* 1462:11–28
- Friedrich CL, Moyles D, Beveridge TJ, Hancock REW (2000) Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. *Antimicrob Agents Chemother* 44:2086–2092
- Cudic M, Otvos L Jr (2002) Intracellular targets of antibacterial peptides. *Curr Drug Targets* 3:101–106
- Park CB, Kim HS, Kim SC (1998) Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. *Biochem Biophys Res Commun* 244:253–257
- Carlsson A, Nystrom T, de Cock H, Bennich H (1998) Attacin—an insect immune protein—binds LPS and triggers the specific inhibition of bacterial outer-membrane protein synthesis. *Microbiology* 144:2179–2188
- Boman HG, Agerberth B, Boman A (1993) Mechanisms of action on *Escherichia coli* of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. *Infect Immun* 61:2978–2984
- Otvos L Jr, Insug O, Rogers ME, Consolvo PJ, Condie BA, Lovas S, Bulet P, Blaszczyk-Thurin M (2000) Interaction between heat shock proteins and antimicrobial peptides. *Biochemistry* 39:14150–14159
- Leikina E, Delano-Ayari H, Melikov K, Cho MS, Chen A, Waring AJ, Wang W, Xie Y, Loo JA, Lehrer RI, Chernomordik LV (2005) Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. *Nat Immunol* 6:995–1001
- Rosenfeld Y, Papo N, Shai Y (2006) Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. *J Biol Chem* 281:1636–1643
- Hoover DM, Boulegue C, Yang D, Oppenheim JJ, Tucker KD, Lu W, Lubkowski J (2002) The structure of human MIP-3/CCL20: linking antimicrobial and CCR6 receptor binding activities with human β -defensins. *J Biol Chem* 277:37647–37654
- Yang D, Biragyn A, Kwak LW, Oppenheim JJ (2002) Mammalian defensins in immunity: more than just microbicidal. *Trends Immunol* 23:291–296
- Bals R, Wilson JM (2003) Cathelicidins—a family of multifunctional antimicrobial peptides. *Cell Mol Life Sci* 60:711–720
- Fernandez Guerrero ML, Ramos JM, Marrero J, Cuenca M, Fernandez Roblas R, de Gorgolas M (2003) Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality. *Int J Infect Dis* 7:46–52
- Ganz T, Metcalf JA, Gallin JI, Boxer LA, Lehrer RI (1988) Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and ‘specific’ granule deficiency. *J Clin Invest* 82:552–556
- Putsep K, Carlsson G, Boman HG, Andersson M (2002) Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. *Lancet* 360:1144–1149
- Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med* 347:1151–1160
- Scott MS, Davidson DJ, Gold MR, Bowdish D, Hancock REW (2002) The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. *J Immunol* 169:3883–3891
- Giacometti A, Cirioni O, Ghiselli R, Mocchegiani F, D’Amato G, Circo R, Orlando F, Skerlavaj B, Silvestri C, Saba V, Zanetti M, Scalise G (2004) Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. *Am J Respir Crit Care Med* 169:187–194
- Moser C, Weiner DJ, Lysenko E, Bals R, Weiser JN, Wilson JM (2002) β -Defensin 1 contributes to pulmonary innate immunity in mice. *Infect Immun* 70:3068–3072
- Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, Pestonjamas V, Piraino J, Huttner K, Gallo RL (2001) Innate antimicrobial peptide protects the skin from invasive bacterial infection. *Nature* 414:454–457
- Salzman NH, Ghosh D, Huttner KM, Paterson Y, Bevins CL (2003) Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. *Nature* 422:522–526
- Goldstein BP, Wei J, Greenberg K, Novick RJ (1998) Activity of nisin against *Streptococcus pneumoniae*, in vitro, and in a mouse infection model. *Antimicrob Chemother* 42:277–278
- Lee PH, Ohtake T, Zaiou M, Murakami M, Rudisill JA, Lin KH, Gallo RL (2005) Expression of an additional cathelicidin

- antimicrobial peptide protects against bacterial skin infection. *Proc Natl Acad Sci USA* 102:3750–3755
35. Mygind PH, Fischer RL, Schnorr KM, Hansen MT, Sonksen CP, Ludvigsen S, Raventos D, Buskov S, Christensen B, De Maria L, Taboureau O, Yaver D, Elvig-Jorgensen SG, Sorensen MV, Christensen BE, Kjaerulff S, Frimodt-Moller N, Lehrer RI, Zasloff M, Kristensen HH (2005) Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. *Nature* 437:975–980
 36. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM (1999) Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. *Infect Immun* 67:6084–6089
 37. Braff MH, Zaiou M, Fierer J, Nizet V, Gallo RL (2005) Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens. *Infect Immun* 73:6771–6781
 38. Carretero M, Del Rio M, Garcia M, Escamez MJ, Mirones I, Rivas L, Balague C, Jorcano JL, Larcher F (2004) A cutaneous gene therapy approach to treat infection through keratinocyte-targeted overexpression of antimicrobial peptides. *FASEB J* 18:1931–1933
 39. Jacobsen F, Mittler D, Hirsch T, Gerhards A, Lehnhardt M, Voss B, Steinau HU, Steinstraesser L (2005) Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections. *Gene Ther* 12:1494–1502
 40. Peschel A (2002) How do bacteria resist human antimicrobial peptides? *Trends Microbiol* 10:179–186
 41. Peschel A, Sahl HG (2006) The co-evolution of host cationic antimicrobial peptides and microbial resistance. *Nat Rev Microbiol* 4:529–536
 42. Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bristol G, Zack JA, Waring AJ, Yang OO, Lehrer RI (2002) Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. *Proc Natl Acad Sci USA* 99:1813–1818
 43. Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmaso EA, Fu S, Pham T, Mei J, Ho JJ, Zhang W, Lopez P, Ho DD (2002) Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. *Science* 298:995–1000
 44. Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI (2004) Activity of alpha- and theta-defensins against primary isolates of HIV-1. *J Immunol* 173:515–520
 45. Zhang K, Lu Q, Zhang Q, Hu X (2004) Regulation of activities of NK cells and CD4 expression in T cells by human HNP-1, -2, and -3. *Biochem Biophys Res Commun* 323:437–444
 46. Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT (2006) Human alpha-defensins block papillomavirus infection. *Proc Natl Acad Sci USA* 103:1516–1521
 47. Braidia L, Boniotto M, Pontillo A, Tovo PA, Amoroso A, Crovella S (2004) A single-nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children. *AIDS* 18:1598–1600
 48. Steinstraesser L, Tippler B, Mertens J, Lamme E, Homann HH, Lehnhardt M, Wildner O, Steinau HU, Uberla K (2005) Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. *Retrovirology* 2:2
 49. Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY (2004) Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. *J Immunol* 172:1763–1767
 50. Lorin C, Saidi H, Belaid A, Zairi A, Baleux F, Hocini H, Belec L, Hani K, Tangy F (2005) The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. *Virology* 334:264–275
 51. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. *Cell* 47:333–348
 52. Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. *Annu Rev Immunol* 17:657–700
 53. Gallo SA, Wang W, Rawat SS, Jung G, Waring AJ, Cole AM, Lu H, Yan X, Daly NL, Craik DJ, Jiang S, Lehrer RI, Blumenthal R (2006) θ -defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. *J Biol Chem* 281:18787–18792
 54. Feng Z, Dubyak GR, Lederman MM, Weinberg A (2006) Cutting edge: human beta defensin 3—a novel antagonist of the HIV-1 coreceptor CXCR4. *J Immunol* 177:782–786
 55. Lupetti A, Danesi R, van 't Wout JW, van Dissel JT, Senesi S, Nibbering PH (2002) Antimicrobial peptides: therapeutic potential for the treatment of Candida infections. *Expert Opin Investig Drugs* 11:309–318
 56. Lehrer R, Ganz T, Szklarek D, Selsted M (1988) Modulation of the in situ candidiacidal activity of human neutrophil defensins by target cell metabolism and divalent cations. *J Clin Invest* 81:1829–1835
 57. Selsted M, Szklarek D, Ganz T, Lehrer R (1985) Activity of rabbit leukocyte peptides against *Candida albicans*. *Infect Immun* 49:202–206
 58. Xu T, Levitz SM, Diamond RD, Oppenheim FG (1991) Anticandidal activity of major human salivary histatins. *Infect Immun* 59:2549–2554
 59. Mandel L, Fatehi J (1992) Minor salivary gland sialolithiasis. Review and case report. *N Y State Dent J* 58:31–33
 60. Helmerhorst EJ, Venuleo C, Beri A, Oppenheim FG (2005) *Candida glabrata* is unusual with respect to its resistance to cationic antifungal proteins. *Yeast* 22:705–714
 61. Shai Y (1995) Molecular recognition between membrane-spanning polypeptides. *TIBS* 20:460–464
 62. Hugosson M, Andreu D, Boman HG, Glaser E (1994) Antibacterial peptides and mitochondrial coupling, respiration and protein import. *Eur J Biochem* 223:1027–1033
 63. Gwadz RW, Kaslow D, Lee JY, Maloy WL, Zasloff M, Miller LH (1989) Effects of magainins and cecropins on the sporogonic development of malaria parasites in mosquitoes. *Infect Immun* 57:2628–2633
 64. Huang CM, Chen HC, Zierdt CH (1990) Magainin analogs effective against pathogenic protozoa. *Antimicrob Agents Chemother* 34:1824–1826
 65. McGwire BS, Olson CL, Tack BF (1993) Killing of African trypanosomes by antimicrobial peptides. *J Infect Dis* 168:146–152
 66. Zuyderduyn S, Ninaber DK, Hiemstra PS, Rabe KF (2006) The antimicrobial peptide LL-37 enhances IL-8 release by human airway smooth muscle cells. *J Allergy Clin Immunol* 117:1328–1335
 67. Braff MH, Hawkins MA, Di Nardo A, Lopez-Garcia B, Howell MD, Wong C, Lin K, Streib JE, Dorschner R, Leung DY, Gallo RL (2005) Structure–function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. *J Immunol* 174:4271–4278
 68. Tjabringa GS, Aarbiou J, Ninaber DK, Drijfhout JW, Sorensen OE, Borregaard N, Rabe KF, Hiemstra PS (2003) The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. *J Immunol* 171:6690–6696
 69. Scott MG, Hancock REW (2000) Cationic antimicrobial peptides and their multifunctional role in the immune system. *Crit Rev Immunol* 20:407–431
 70. Gallo RL, Nizet V (2003) Endogenous production of antimicrobial peptides in innate immunity and human disease. *Curr Allergy Asthma Rep* 3:402–409

71. Harder J, Schroder JM (2005) Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. *J Leukoc Biol* 77:476–486
72. Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM (2005) Antimicrobial psoriasin (S100A7) protects human skin from *Escherichia coli* infection. *Nat Immunol* 6:57–64
73. Rieg S, Steffen H, Seeber S, Humeny A, Kalbacher H, Dietz K, Garbe C, Schittek B (2005) Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. *J Immunol* 174:8003–8010
74. Oono T, Huh WK, Shirafuji Y, Akiyama H, Iwatsuki K (2003) Localization of human beta-defensin-2 and human neutrophil peptides in superficial folliculitis. *Br J Dermatol* 148:188–191
75. Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S, Wigzell H, Gudmundsson GH (1997) The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. *J Biol Chem* 272:15258–15263
76. Marta Guarna M, Coulson R, Rubinchik E (2006) Anti-inflammatory activity of cationic peptides: application to the treatment of acne vulgaris. *FEMS Microbiol Lett* 257:1–6
77. McInturff JE, Wang SJ, Machleidt T, Lin TR, Oren A, Hertz CJ, Krutzik SR, Hart S, Zeh K, Anderson DH, Gallo RL, Modlin RL, Kim J (2005) Granulysin-derived peptides demonstrate antimicrobial and anti-inflammatory effects against *Propionibacterium acnes*. *J Invest Dermatol* 125:256–263
78. Friedland HD, Sharp DD, Robinson JR (2003) Double-blind, randomized, vehicle-controlled study to assess the safety and efficacy of MBI 594AN in the treatment of acne vulgaris. Abstracts of the 61st annual meeting of American Academy of Dermatology 61:22
79. Bals R, Hiemstra PS (2006) Antimicrobial peptides in COPD-basic biology and therapeutic applications. *Curr Drug Targets* 7:743–750
80. Beisswenger C, Bals R (2005) Antimicrobial peptides in lung inflammation. *Chem Immunol Allergy* 86:55–71
81. Ashitani J, Mukae H, Nakazato M, Ihi T, Mashimoto H, Kadota J, Kohno S, Matsukura S (1998) Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis. *Eur Respir J* 11:104–111
82. Smith JJ, Travis SM, Greenberg EP, Welsh MJ (1996) Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. *Cell* 85:229–236
83. Bals R, Wang X, Wu Z, Freeman T, Bafna V, Zasloff M, Wilson JM (1998) Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. *J Clin Invest* 102:874–880
84. Bals R, Weiner DJ, Mosconi AD, Meegalla RL, Wilson JM (1999) Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. *Infect Immun* 67:6084–6089
85. Bals R, Weiner DJ, Meegalla RL, Wilson JM (1999) Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. *J Clin Invest* 103:1113–1117
86. Tani K, Murphy WJ, Chertov O, Salcedo R, Koh CY, Utsunomiya I, Funakoshi S, Asai O, Herrmann SH, Wang JM, Kwak LW, Oppenheim JJ (2000) Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. *Int Immunol* 12:691–700
87. Oppenheim JJ, Biragyn A, Kwak LW, Yang D (2003) Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. *Ann Rheum Dis* 62:17–21
88. Lu Q, Jin L, Darveau RP, Samaranayake LP (2004) Expression of human beta-defensins-1 and -2 peptides in unresolved chronic periodontitis. *J Periodontol Res* 39:221–227
89. Gusman H, Travis J, Helmerhorst EJ, Potempa J, Troxler RF, Oppenheim FG (2001) Salivary histatin 5 is an inhibitor of both host and bacterial enzymes implicated in periodontal disease. *Infect Immun* 69:1402–1408
90. Yoshinari M, Kato T, Matsuzaka K, Hayakawa T, Inoue T, Oda Y, Okuda K, Shimono M (2006) Adsorption behavior of antimicrobial peptide histatin 5 on PMMA. *J Biomed Mater Res B Appl Biomater* 77:47–54
91. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H Jr, Fellermann K, Ganz T, Stange EF, Bevins CL (2005) Reduced paneth cell alpha-defensins in ileal Crohn's disease. *Proc Natl Acad Sci USA* 102:18129–18134
92. Bevins CL (2006) Paneth cell defensins: key effector molecules of innate immunity. *Biochem Soc Trans* 34:263–266
93. Kobayashi KS, Chamailard M, Ogura Y, Henegariu O, Inohara N, Nunez G, Flavell RA (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. *Science* 307:731–734
94. Schaubert J, Rieger D, Weiler F, Wehkamp J, Eck M, Fellermann K, Scheppach W, Gallo RL, Stange EF (2006) Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. *Eur J Gastroenterol Hepatol* 18:615–62
95. Fahlgren A, Hammarstrom S, Danielsson A, Hammarstrom ML (2004) beta-defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. *Clin Exp Immunol* 137:379–385
96. Wehkamp J, Schwind B, Herrlinger KR, Baxmann S, Schmidt K, Duchrow M, Wohlschlagel C, Feller AC, Stange EF, Fellermann K (2002) Innate immunity and colonic inflammation: enhanced expression of epithelial alpha-defensins. *Dig Dis Sci* 47:1349–1355
97. Baker MA, Maloy WL, Zasloff M, Jacob LS (1993) Anticancer efficacy of magainin2 and analogue peptides. *Cancer Res* 53:3052–3057
98. Soballe PW, Maloy WL, Myrnga ML, Jacob LS, Herlyn M (1995) Experimental local therapy of human melanoma with lytic magainin peptides. *Int J Cancer* 60:280–284
99. Lehmann J, Retz M, Sidhu SS, Suttman H, Sell M, Paulsen F, Harder J, Unteregger G, Stockle M (2006) Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. *Eur Urol* 50:141–147
100. Moore AJ, Devine DA, Bibby MC (1994) Preliminary experimental anticancer activity of cecropins. *Pept Res* 7:265–269
101. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K, Azuma I (1998) Bovine lactoferrin and lactoferricin inhibit tumor metastasis in mice. *Adv Exp Med Biol* 443:285–291
102. Mader JS, Salsman J, Conrad DM, Hoskin DW (2005) Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. *Mol Cancer Ther* 4:612–624
103. Eliassen LT, Berge G, Leknessund A, Wikman M, Lindin I, Lokke C, Ponthan F, Johnsen JI, Sveinbjornsson B, Kogner P, Flaegstad T, Rekdal O (2006) The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. *Int J Cancer* 119:493–500
104. Eliassen LT, Berge G, Sveinbjornsson B, Svendsen JS, Vorland LH, Rekdal O (2002) Evidence for a direct antitumor mechanism of action of bovine lactoferricin. *Anticancer Res* 22:2703–2710
105. Bateman A, Singh A, Jothy S, Fraser R, Esch F, Solomon S (1992) The levels and biologic action of the human neutrophil granule peptide HP-1 in lung tumors. *Peptides* 13:133–139
106. Mizukawa N, Sugiyama K, Kamio M, Yamachika E, Ueno T, Fukunaga J, Takagi S, Sugahara T (2000) Immunohistochemical staining of human alpha-defensin-1 (HNP-1), in the submandibular glands of patients with oral carcinomas. *Anticancer Res* 20:1125–1127
107. Muller CA, Markovic-Lipkovski J, Klatt T, Gamper J, Schwarz G, Beck H, Deeg M, Kalbacher H, Widmann S, Wessels JT,

- Becker V, Muller GA, Flad T (2002) Human alpha-defensins HNP-1, -2, and -3 in renal cell carcinoma influences on tumor cell proliferation. *Am J Pathol* 160:1311–1324
108. Holterman DA, Diaz JI, Blackmore PF, Davis JW, Schellhammer PF, Corica A, Semmes OJ, Vlahou A (2006) Overexpression of alpha-defensin is associated with bladder cancer invasiveness. *Urol Oncol* 24:97–108
109. Papo N, Shai Y (2005) Host defense peptides as new weapons in cancer treatment. *Cell Mol Life Sci* 62:784–90
110. Glass CK, Witztum JL (2001) Atherosclerosis. the road ahead. *Cell* 104:503–516
111. Higazi AA, Lavi E, Bdeir K, Ulrich AM, Jamieson DG, Rader DJ, Usher DC, Kane W, Ganz T, Cines DB (1997) Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. *Blood* 89:4290–4298
112. Barnathan ES, Raghunath PN, Tomaszewski JE, Ganz T, Cines DB, Higazi AA (1997) Immunohistochemical localization of defensin in human coronary vessels. *Am J Pathol* 150:1009–1020
113. Higazi AA, Nassar T, Ganz T, Rader DJ, Udassin R, Bdeir K, Hiss E, Sachais BS, Williams KJ, Leitersdorf E, Cines DB (2000) The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. *Blood* 96:1393–1398
114. Higazi AA, Ganz T, Kariko K, Cines DB (1996) Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. *J Biol Chem* 271:1760–1765
115. Chavakis T, Cines DB, Rhee JS, Liang OD, Schubert U, Hammes HP, Higazi AA, Nawroth PP, Preissner KT, Bdeir K (2004) Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. *FASEB J* 18:1306–1308
116. Hooper LV, Stappenbeck TS, Hong CV, Gordon JI (2003) Angiogenins: a new class of microbicidal proteins involved in innate immunity? *Nat Immunol* 4:269–273
117. Kougiaris P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C (2006) Neutrophil antimicrobial peptide alpha-defensin causes endothelial dysfunction in porcine coronary arteries. *J Vasc Surg* 43:357–363
118. Edfeldt K, Agerberth B, Rottenberg ME, Gudmundsson GH, Wang XB, Mandal K, Xu Q, Yan ZQ (2006) Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. *Arterioscler Thromb Vasc Biol* 26:1551–1557
119. Post MJ, Sato K, Murakami M, Bao J, Tirziu D, Pearlman JD, Simons M (2006) Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. *Am J Physiol Regul Integr Comp Physiol* 290:R494–R500
120. Li YM, Tan AX, Vlassara H (1995) Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. *Nat Med* 1:1057–1061
121. Paulsen F, Pufe T, Petersen W, Tillmann B (2001) Expression of natural peptide antibiotics in human articular cartilage and synovial membrane. *Clin Diagn Lab Immunol* 8:1021–1023
122. Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, Petersen W (2002) Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. *J Pathol* 198:369–377
123. Bals R, Wang X, Meegalla RL, Wattler S, Weiner DJ, Nehls MC, Wilson JM (1999) Mouse beta-defensin 3 is an inducible antimicrobial peptide expressed in the epithelia of multiple organs. *Infect Immun* 67:3542–3547
124. Varoga D, Pufe T, Mentlein R, Kohrs S, Grohmann S, Tillmann B, Hassenpflug J, Paulsen F (2005) Expression and regulation of antimicrobial peptides in articular joints. *Ann Anat* 187:499–508
125. Varoga D, Pufe T, Harder J, Schroder JM, Mentlein R, Meyer-Hoffert U, Goldring MB, Tillmann B, Hassenpflug J, Paulsen F (2005) Human beta-defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. *Arthritis Rheum* 52:1736–1745
126. Harder J, Bartels J, Christophers E, Schroder JM (1997) A peptide antibiotic from human skin. *Nature* 387:861
127. Singh PK, Jia HP, Wiles K, Hesselberth J, Liu L, Conway BA, Greenberg EP, Valore EV, Welsh MJ, Ganz T, Tack BF, McCray PB Jr (1998) Production of beta-defensins by human airway epithelia. *Proc Natl Acad Sci USA* 95:1491–1496
128. Folkman J, D'Amore PA (1996) Blood vessel formation: what is its molecular basis? *Cell* 87:1153–1155
129. Dorschner RA, Pestonjamas VK, Tamakuwala S, Ohtake T, Rudisill J, Nizet V, Agerberth B, Gudmundsson GH, Gallo RL (2001) Cutaneous injury induces the release of cathelicidin antimicrobial peptides active against group A *Streptococcus*. *J Invest Dermatol* 117:91–97
130. Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard N (2003) Related wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. *J Immunol* 170:5583–5589
131. Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, Hale-Donze H, McGrady G, Song XY, Wahl SM (2000) Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. *Nat Med* 6:1147–1153
132. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, Stahle-Backdahl M (2003) The cathelicidin antimicrobial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. *J Invest Dermatol* 120:379–389
133. Milner SM, Ortega MR (1999) Reduced antimicrobial peptide expression in human burn wounds. *Burns* 25:411–413
134. Ortega MR, Ganz T, Milner SM (2000) Human beta defensins is absent in burn blister fluid. *Burns* 26:724–726
135. Steinstraesser L, Klein RD, Aminlari A, Fan MH, Khilani V, Remick DG, Su GL, Wang SC (2001) PEG-1 enhances bacterial killing in thermally injured skin. *Crit Care Med* 29:1431–1437
136. Kocuzilla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T, Issbrucker K, Unterberger P, Zaiou M, Leberer C, Karl A, Raake P, Pfosser A, Boekstegers P, Welsch U, Hiemstra PS, Vogelmeier C, Gallo RL, Clauss M, Bals R (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. *J Clin Invest* 111:1665–1672
137. Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, Hampton TG, Sellke F, Carmeliet P, Simons M (2000) PR39, a peptide regulator of angiogenesis. *Nat Med* 6:49–55
138. Paquette DW, Simpson DM, Friden P, Braman V, Williams RC (2002) Safety and clinical effects of topical histatin gels in humans with experimental gingivitis. *J Clin Periodontol* 29:1051–1058
139. Isaacson RE (2003) MBI-226. *Micrologix/Fujisawa*. *Curr Opin Investig Drugs* 4:9991003
140. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM (1997) Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. *Cell* 88:553–560
141. Marr AK, Gooderham WJ, Hancock RE (2006) Antibacterial peptides for therapeutic use: obstacles and realistic outlook. *Curr Opin Pharmacol* 6:468–472
142. Tanida T, Okamoto T, Okamoto A, Wang H, Hamada T, Ueta E, Osaki T (2003) Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. *J Oral Pathol & Med* 32:586–594